IUPAC/Chemical Name
(1-aminobutane-1,1-diyl)bis(phosphonic acid)
InChi Key
XLIREHXMRXKQIV-UHFFFAOYSA-N
InChi Code
InChI=1S/C4H13NO6P2/c1-2-3-4(5,12(6,7)8)13(9,10)11/h2-3,5H2,1H3,(H2,6,7,8)(H2,9,10,11)
SMILES Code
CCCC(P(O)(O)=O)(P(O)(O)=O)N
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
233.10
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Adami S, Gatti D, Bertoldo F, Rossini M, Fratta-Pasini A, Zamberlan N, Facci E, Lo Cascio V. The effects of menopause and estrogen replacement therapy on the renal handling of calcium. Osteoporos Int. 1992 Jul;2(4):180-5. doi: 10.1007/BF01623924. PMID: 1611223.
2: Passeri M, Baroni MC, Pedrazzoni M, Vescovi PP. Esperienze di trattamento del dolore cronico del rachide nella osteoporosi involutiva [Treatment experience with chronic spinal pain in involutional osteoporosis]. Ann Ital Med Int. 1992 Jul-Sep;7(3 Suppl):137S-153S. Italian. PMID: 1297392.
3: Adzamli IK, Blau M. Phosphonate-modified GdDTPA complexes. I. NMRD study of the solution behavior of new tissue-specific contrast agents. Magn Reson Med. 1991 Jan;17(1):141-8. doi: 10.1002/mrm.1910170118. PMID: 2067390.
4: Bickerstaff DR, O'Doherty DP, McCloskey EV, Hamdy NA, Mian M, Kanis JA. Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy. Bone. 1991;12(1):17-20. doi: 10.1016/8756-3282(91)90049-o. PMID: 2054231.
5: Mian M, Adami S, Rigo A, Bonazzi L, Braga V, Lo Cascio V. Effects of vitamin D metabolites and bisphosphonates on fibronectin release from monocyte-derived macrophages. Int J Tissue React. 1991;13(3):139-43. PMID: 1835718.
6: Thompson DD, Seedor JG, Weinreb M, Rosini S, Rodan GA. Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats. J Bone Miner Res. 1990 Mar;5(3):279-86. doi: 10.1002/jbmr.5650050312. PMID: 2333787.
7: Adami S, Bolzicco GP, Rizzo A, Salvagno G, Bertoldo F, Rossini M, Suppi R, Lo Cascio V. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner. 1987 Aug;2(5):395-404. PMID: 2975514.
